On August 31, 2017, UACT sent a letter to Francis Collins, the Director of the National Institutes of Health (NIH), regarding the emerging chimeric antigen receptor T-cell (CAR T) technologies that are currently being developed across a number of pharmaceutical companies and institutions. ¬†On August 30, 2017, the Food and Drug Administration (FDA) made the first approval of a CAR T treatment, a leukemia treatment by Novartis for children and young adults. Novartis announced it would charge $475,000 for the treatment. In the UACT letter to Dr. Collins, we ask the NIH to communicate more information to public regarding the NIH role in developing, patentingRead More →

By Julie Chmelikova There are currently 28 EU member states, yet their health care systems vary substantially and are based on national policies. Reimbursement models, health care expenditures, availability of resources and accessibility of drugs are just some of the aspects of health care where major differences occur. Access to cancer drugs is an especially pressing issue that demonstrates vividly the differences in access to health care across the EU. The inequality is evident for example in the case of Poland, Hungary and Slovakia, where patients do not have access to many innovative cancer drugs, such as Kadcyla (breast cancer), Jevtana (prostate cancer), Dacogen (acuteRead More →